Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
The lab will facilitate the development of herbal and natural-based solutions
Subscribe To Our Newsletter & Stay Updated
